Cardiac amyloidosis

Purpose: The aim of the present article was to review the recent developments in diagnosis, prognostication and management of cardiac amyloidosis. Methods: Available scientific literature on cardiac amyloidosis has been critically reviewed. Results: Different precursors cause different forms of cardiac amyloidosis with different outcomes and therapeutic options. Cardiac involvement determines not-specific symptoms and the diagnosis remains often a challenge for cardiologists. As a consequence, patients continue to present end-stage heart failure when possible effective therapeutic interventions are of limited utility. Conclusions: Advances in cardiac biomarkers assessment, echocardiography, cardiac magnetic resonance and nuclear molecular imaging have improved the ability of cardiologists in the recognition and prognostic stratification of this not so rare, not so untreatable cardiac disease.